Lead Product(s): Tucidinostat
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Meiji Seika Pharma Co Ltd.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 08, 2020
HUYABIO will complete the development of HBI-8000 for PTCL and ATL in Japan for commercialization by Meiji who will hold exclusive sales and marketing rights.